|
Jul 23, 2012, 01.40 PM IST
Generics drugs maker Aurobindo Pharma has received final approval from US Food and Drugs Administration (FDA) to manufacture and market Metformin Hydrochloride extended-release tablets in 500mg and 750mg strength.
Generics drugs maker Aurobindo Pharma has received final approval from US Food and Drugs Administration (FDA) to manufacture and market Metformin Hydrochloride extended-release tablets in 500mg and 750mg strength. Aurobindo's product is a copy of Bristol Myers Squibb's Glucophage and is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type-2 diabetes. Metformin Hydrochloroide has annual US sales of around USD 230 million, the company said on Monday. The product has been approved out of Unit-III formulations facility in Hyderabad, it added. Aurobindo now has 127 final approvals and 26 tentative approvals from US FDA. Aurobindo Pharma shares were up 0.4% at Rs 108.80 on NSE in noon trade.
Set email alert for Tags: Aurobindo Pharma, Metformin, extended release, diabetes control, Bristol Myers Squibb, Glucophage, generic, copy, drug,
|
 From DJ EU Officials Spain Aid Cap Of 100 Bn Euros 'should Be Enough'  The latest earning numbers FIRST on CNBC-TV18
News Videos
|
